http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SE-8503110-L

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97a285d8ecd0184a7e5d89a1e4e07997
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D285-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D285-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-433
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D283-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
filingDate 1985-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8462f1f2732f501b362689ba82a7be1d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe72783b6815e0e678b942d2ce71c3ab
publicationDate 1985-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber SE-8503110-L
titleOfInvention SUBSTITUTED 3,4-DIAMINO-1,25-THIADIAZOLES WITH HISTAMINE-H? 712 RECEPTOR ANTAGONIST ACTIVITY
abstract Histamine H2-receptor antagonists of the formula <IMAGE> I wherein A, m, Z, n and R1 are as defined herein, and their nontoxic pharmaceutically acceptable salts are novel anti-ulcer agents which are prepared by ring closure of a substituted ethanediimidamide of the formula <IMAGE> II
priorityDate 1984-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410440415
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15264879

Total number of triples: 34.